
Exact Sciences (EXAS) Stock Forecast & Price Target
Exact Sciences (EXAS) Analyst Ratings
Bulls say
Exact Sciences is positioned for significant growth, particularly with its Cologuard screening test, which is expected to expand its market share from approximately 15% currently to over 40%, indicating strong adoption potential. The company's recent performance has been bolstered by a remarkable 22% year-over-year growth in its core screening business, alongside positive momentum from innovative products like Cancerguard, anticipated to enhance marketing efforts and revenue generation in the near term. Furthermore, the increase in pricing for Cologuard Plus, reaching approximately $592 per test, coupled with strategic initiatives aimed at increasing screening volume to 30 million people by 2027, underscores a robust financial outlook for Exact Sciences.
Bears say
The financial outlook for Exact Sciences, as indicated, is negatively impacted by several fundamental metrics. The company has faced persistent net losses, raising concerns about its ability to achieve and maintain GAAP profitability. Additionally, Cologuard's demand sensitivity to marketing expenditures and subdued revenue projections, estimated at $4.0 billion for 2027, illustrate potential challenges in meeting growth expectations amidst an uncertain market environment.
This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.
Exact Sciences (EXAS) Analyst Forecast & Price Prediction
Start investing in Exact Sciences (EXAS)
Order type
Buy in
Order amount
Est. shares
0 shares